
Opinion|Videos|January 14, 2025
The Impact of Targeted Gene Therapy and Nadofaragene Firadenovec on BCG-Unresponsive NMIBC
Author(s)Max Kates, MD
A panelist discusses how targeted gene therapy, particularly nadofaragene firadenovec, represents a paradigm shift in BCG-unresponsive NMIBC treatment.
Advertisement
Episodes in this series

- How has the introduction of targeted gene therapy changed the way you approach managing BCG-unresponsive NMIBC?
- What are the broader implications of using gene therapy to treat BCG-unresponsive NMIBC, and how does nadofaragene firadenovec fit into this landscape overall?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
HHS requests testosterone therapy label updates, citing new safety data
2
Unmet needs and emerging solutions in MRI-guided prostate cancer care
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Pearls & Perspectives: The Power of Advocacy in Sexual Medicine, With Rachel Rubin, MD
5









